Tumor Enucleation for Renal Cell Carcinoma by Smith, Zachary L & Malkowicz, Bruce
Smith and Malkowicz                                                                                                                         Tumor enucleation                                                                                       
Journal of Kidney Cancer and VHL 2015; 2(2):64-69             http://jkcvhl.com  
 
Journal of Kidney Cancer and VHL 2015; 2(2):64-69 
DOI: http://dx.doi.org/10.15586/jkcvhl.2015.27 
 
Review Article 
 
Tumor Enucleation for Renal Cell Carcinoma 
 
Zachary L. Smith, S. Bruce Malkowicz 
 
Division of Urology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA 
 
Abstract 
 
The increased number of small renal masses (SRMs) detected annually has led to a rise in 
the use of nephron-sparing surgery (NSS).  These techniques aim to preserve the largest 
amount of healthy renal tissue possible while maintaining the same oncologic outcomes as 
radical nephrectomy (RN).  Additionally, partial nephrectomy (PN) has been linked to a 
lower risk of chronic kidney disease, cardiovascular morbidity, and mortality when 
compared to RN.  There has been continual progress toward resecting less renal 
parenchyma.  While the predominant surgical method of performing NSS is through 
traditional PN, simple enucleation (SE) of the tumor has increased in popularity over recent 
years.  SE is a technique that aims to preserve the maximal amount of renal parenchyma 
possible by utilizing the renal tumor pseudocapsule to bluntly separate the lesion from its 
underlying parenchyma, offering the smallest possible margin of excised healthy renal 
tissue.  Several studies have demonstrated the oncological safety of SE compared with PN 
in the treatment of SRMs, with lower overall incidence of positive surgical margins.  
Additionally, SE has been shown to have similar 5- and 10-year progression-free and 
cancer-specific survival as PN.  We present a review of the literature and an argument for 
SE to be a routine consideration in the treatment of all renal tumors amenable to NSS. 
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Introduction 
 
It is estimated that there will be 61,560 
new cases of kidney cancer in the United 
States in 2015, and an estimated 14,080 
deaths (1).  This incidence has been on the 
rise over the last three decades and is 
generally attributed to the increased 
utilization of cross-sectional imaging across 
all disciplines (2,3). Despite this increasing 
incidence, the estimated 5-year relative 
survival rate has improved from 50% in 
1975-1977 to 74% in 2004-2010 (1).  This 
improvement in survival may be ascribed to 
the stage migration which has been seen 
over the last two decades, with more 
patients presenting at stage I than any 
other stage (4).  Alternatively, it could be 
attributed to the paralleling increase in 
treatment of renal tumors with improved 
surgical techniques and medical therapies 
(3). 
 
Nephron-sparing surgery 
 
This increased number of low stage small 
renal masses (SRMs) detected annually has 
led to an evolution in the treatment of renal 
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cell carcinoma (RCC); specifically, a rise in 
the use of nephron-sparing surgery (NSS) 
(4-7).  These techniques aim to preserve the 
largest amount of healthy renal tissue 
possible while maintaining the same 
oncologic outcomes as radical nephrectomy 
(RN).  Additionally, partial nephrectomy 
(PN) has been linked to a lower risk of 
chronic kidney disease (CKD), 
cardiovascular morbidity, and mortality 
when compared to RN (8-11). 
 
While the use of NSS can be traced as far 
back as the late 19th century (12), the 
importance of preventing development or 
worsening of CKD has become increasingly 
evident over recent years.  It is thought 
that resultant CKD is likely the root of the 
cardiovascular and all-cause mortality seen 
in patients treated with RN or PN 
(10,13,14).  Unfortunately, one study found 
a baseline CKD (stage III or greater) in 22% 
of patients presenting for surgical 
management of their renal tumors, with 
this incidence increasing to 40% in 
patients aged 70 years (15).  For these 
reasons, current guidelines support the use 
of NSS for the treatment of the SRM 
whenever technically feasible (6,16). 
 
Simple enucleation 
 
In 1950, Benjamin Abeshouse wrote “Few 
procedures provide the urologist with more 
satisfaction than those that preserve renal 
function” (17).  While Dr. Abeshouse may 
have practiced urology prior to the 
availability of the robust data we now 
possess, his statement rings true to this 
day.  On this principle, NSS has taken a 
prominent position at the helm of the 
treatment of renal tumors.  Likewise, there 
has been continual progress toward 
resecting less and less renal parenchyma.  
While the predominant surgical method of 
performing NSS is through traditional PN, 
simple enucleation (SE) of the tumor has 
increased in popularity over recent years 
(18-21).  SE is a technique that aims to 
preserve the maximal amount of renal 
parenchyma possible by utilizing the renal 
tumor pseudocapsule to bluntly separate 
the lesion from its underlying parenchyma.  
This method of NSS has been used for 
more than three decades with success (22-
24).   The largest contribution to the body 
of literature on SE has been published by 
the University of Florence group and their 
affiliates (18,19,21,25-30). 
 
Technique 
 
The renal parenchyma adjacent to the 
tumor is incised.  Using a blunt dissecting 
instrument (e.g. empty knife handle, closed 
Metzenbaum scissors, small Yankauer 
suction tip), the tumor and its 
pseudocapsule are bluntly separated from 
the adjacent renal parenchyma.  This 
natural cleavage plane between the tumor 
and the normal parenchyma allows for 
removal of the lesion without concomitant 
removal of any visible rim of normal renal 
tissue.  Any large vessels traversing this 
plane can be ligated with clips or sutures 
during the removal.  As with PN, following 
removal of the lesion, the resection site 
may be ablated with an energy source (e.g. 
Nd-YAG laser or Argon beam laser). 
 
The procedure may be performed with or 
without hilar vessel clamping.  Unlike PN, 
SE is often met with much less bleeding 
when done without vessel clamping due to 
the lack of any sizable entrance into renal 
parenchyma (19,20).  Additionally, the 
procedure may be performed in an open or 
robotic-assisted laparoscopic fashion with 
equivalent outcomes (19,25).  These 
authors have published their own 
institutional experience and methods 
previously (20). 
 
Surgical margins 
 
While traditional thinking was that a 1 cm 
margin was required during PN, this has 
been challenged and disproven in recent 
years.  Many studies have now supported 
margins of all sizes—including <1 mm—as 
being safe, noting that there is no minimal 
requirement to maintain an oncologically 
sound resection (31-36).  These principles 
have been supported in masses up to 7 cm 
(37).  Given these results, the European 
Association of Urology recommends 
obtaining the minimal tumor-free surgical 
margin of healthy tissue that is required, 
thus reducing the risk for local recurrence 
while minimizing any detriment to renal 
function (6). 
 
Overall, positive surgical margins (PSMs) 
are relatively rare events at the time of 
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NSS, with current literature identifying 
positive surgical margin (PSM) rates after 
PN to range from 0% to 7% (29,38-41).  
When investigating the significance of a 
PSM on final pathological analysis, little 
effect on survival has been shown (40-42).  
While a large international, multi-
institutional study found that PSMs may be 
associated with an increased risk of 
recurrence (10.1% vs 2.2%, p=<0.0001), 
they found no effect on overall, cancer-
specific, or recurrence-free survival (42). 
 
Minervini et al have published multiple 
times on the role of pseudocapsule 
penetration on rates of PSM and 
oncological outcomes (26,27).  In their most 
recent analysis of patients undergoing SE, 
51% of specimens had an intact 
pseudocapsule free from neoplastic 
invasion, 35% had capsular penetration on 
the parenchymal side, and 14% had 
invasion into the perirenal adipose tissue 
(left attached to surface of tumor).  None of 
the patients had PSMs on final analysis 
and the 5-year progression-free survival 
(PFS) rates were the same for the first two 
groups, and only worsened with perirenal 
adipose tissue invasion (27).  Additionally, 
penetration into and beyond the 
pseudocapsule is accompanied by a thin 
layer of parenchymal tissue even when no 
efforts are made to leave a rim of healthy 
kidney tissue around the neoplasm (26).  
Thus, with or without microscopic invasion 
into the pseudocapsule, patients 
undergoing SE tend to maintain good 
surgical margin and survival rates. 
 
Several studies have demonstrated the 
oncological safety of SE compared with PN 
in the treatment of SRMs, with lower 
overall incidence of PSMs (28-30).  In a 
large, multicenter retrospective series, the 
Surveillance and Treatment Update Renal 
Cancer (SATURN) study found a PSM rate 
of 0.2% with SE and 3.4% with PN 
(p=<0.001) (28).  Similarly, the prospective 
Italian Registry of Conservative Renal 
Surgery (RECORd) project found PSM rates 
of 1.6% and 7.4% with SE and PN, 
respectively (p=<0.001) (29). 
 
Survival outcomes 
 
Long-term oncologic equivalence between 
SE and PN is now well established 
(20,28,30,43).  Carini et al (30) published 
their experience of SE for SRMs (<4 cm) in 
232 patients with a mean follow up of 76 
months, demonstrating 5- and 10-year 
cancer-specific survival (CSS) of 97% and 
95%, respectively.  Five- and 10-year PFS 
was 96% and 94%, respectively, and there 
were no PSMs or local recurrences.  
Recurrence rates for tumors up to 7 cm in 
the same series also demonstrated similar 
CSS and PFS rates to RN and PN. 
 
The SATURN study published long-term 
oncological outcomes comparing SE (537 
patients) to PN (982 patients) at 54 month 
and 51 month mean follow-up, respectively 
(28).  Similar to the above study, this 
multicenter review also found no difference 
in PFS or CSS between techniques.  The 5- 
and 10-year PFS were 91% and 91% after 
SE and 89% and 82% after PN, respectively 
(p=0.09).  The 5- and 10-year CSS were 
94% and 93% after SE and 94% and 92% 
after PN, respectively (p=0.94). 
 
While most SE studies have focused 
predominantly on comparison to PN, it has 
also been compared against RN and shown 
to have similar outcomes.  Minervini et al 
compared 332 patients who underwent SE 
to 143 matched patients who underwent 
RN with a mean follow-up of 72 and 58 
months, respectively (21).  They found 5-
year and 10-year PFS rates of 95% and 
93% for SE and 91% and 89% for RN, 
respectively (p=“non-significant”).  Five- 
and 10-year CSS rates were 94% and 94% 
for SE and 92% and 89% for RN, 
respectively (p=“non-significant”). 
 
Conclusions 
 
Contemporary literature has shown SE to 
be a widely accepted technique of NSS.  
There is an abundance of data to support 
SE as an oncologically sound alternative to 
PN in appropriately selected tumors.  In the 
arena of renal parenchyma preservation, 
SE offers the smallest possible margin of 
excised healthy renal tissue.  SE should be 
a routine consideration for the treatment of 
all renal tumors. 
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